Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

globenewswire

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis – NEWSnet – News… as it used to be

More Press Releases

May 4, 2026

How to set up the perfect off-grid campsite

May 4, 2026

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026

FSK INVESTOR ALERT: FS KKR Capital Corp Investors with Substantial Losses Have Opportunity to Lead the FS KKR Class Action Lawsuit – RGRD Law

May 4, 2026

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

How to set up the perfect off-grid campsite

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FSK INVESTOR ALERT: FS KKR Capital Corp Investors with Substantial Losses Have Opportunity to Lead the FS KKR Class Action Lawsuit – RGRD Law

TWFG Insurance Acquires APIA Inc., Expanding Specialty MGA Capabilities and Supporting Long-Term Growth